AOD-9604 | 10 vials

AOD9604 is a synthetic 16-amino acid peptide derived from the C-terminal lipolytic domain of human growth hormone (hGH), specifically corresponding to hGH residues 176-191 with a tyrosine substitution at the N-terminus . Originally developed as an anti-obesity drug candidate, it was designed to retain the fat-burning properties of hGH without affecting IGF-1 levels or glucose metabolism .

Key Specifications:

• CAS Number: 221231-10-3

• Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂

• Molecular Weight: 1815.1 g/mol

• Sequence: H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH (cyclic 7→14 disulfide)

• Purity: ≥95-99% (research grade)

• Appearance: White lyophilized powder

• Storage: Store at -20°C

Mechanism of Action: AOD9604 exerts its effects through multiple pathways:

• Lipolysis stimulation: Activates beta-3 adrenergic receptors in adipose tissue, triggering the release of stored fatty acids for energy use

• Lipogenesis inhibition: Suppresses the formation of new fat deposits by inhibiting lipogenic enzymes

• β3-AR upregulation: Increases expression of beta-3 adrenergic receptors in fat cells, enhancing lipolytic sensitivity

• No IGF-1 stimulation: Unlike full hGH, does not elevate IGF-1 levels or affect blood glucose metabolism

Research Applications:

• Weight management: Studied for obesity and fat reduction

• Metabolic disorders: Potential applications in metabolic syndrome

• Joint health: May support cartilage repair and regeneration in osteoarthritis models

• Lipid metabolism: Investigated for effects on cholesterol and fat oxidation

Clinical Trial Data: In a 12-week randomized clinical trial, subjects receiving AOD9604 lost an average of 2.6 kg compared to 0.8 kg in the placebo group , representing approximately 1.8 kg greater loss than placebo . However, development was halted in 2007 following insignificant efficacy in a later 24-week trial .

Important Notice: FOR RESEARCH USE ONLY. NOT FOR HUMAN USE, THERAPEUTIC, OR DIAGNOSTIC APPLICATIONS.